CD8A and neoplasm: To test this hypothesis, we depleted NK cells, CD8+ T cells, and CD4+ T cells by administering mAb PK136 (anti-NK1.1), 2.43 (anti-CD8a), and GK1.5 (anti-CD4) intraperitoneally every 3 days, respectively, before the mice were inoculated with tumor cells.